Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California.
| Revenue (TTM) | $18.07M |
| Gross Profit (TTM) | $-339.11M |
| EBITDA | $-541.62M |
| Operating Margin | -1308.00% |
| Return on Equity | -39.20% |
| Return on Assets | -24.70% |
| Revenue/Share (TTM) | $0.19 |
| Book Value | $12.16 |
| Price-to-Book | 3.03 |
| Price-to-Sales (TTM) | 214.74 |
| EV/Revenue | 145.93 |
| EV/EBITDA | -13.40 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2873.00% |
| Shares Outstanding | $105.44M |
| Float | $95.58M |
| % Insiders | 1.59% |
| % Institutions | 120.02% |
Volatility is currently contracting